{"id":"tofacitinib-tablet","safety":{"commonSideEffects":[{"rate":"null","effect":"Upper respiratory tract infection"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Elevated cholesterol"},{"rate":"null","effect":"Increased creatinine"},{"rate":"null","effect":"Herpes zoster reactivation"}]},"_chembl":{"chemblId":"CHEMBL2103743","moleculeType":"Small molecule","molecularWeight":"504.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tofacitinib is a JAK inhibitor that blocks the JAK-STAT signaling pathway, which is critical for the production of pro-inflammatory cytokines like interferon-gamma, interleukin-2, and tumor necrosis factor-alpha. By inhibiting JAK1 and JAK3 preferentially, it reduces T-cell proliferation and activation, thereby suppressing the inflammatory response in autoimmune and inflammatory conditions.","oneSentence":"Tofacitinib inhibits Janus kinase (JAK) enzymes to suppress inflammatory cytokine signaling and reduce immune-mediated inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:00.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ulcerative colitis"},{"name":"Polyarticular course juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT07281456","phase":"PHASE2","title":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease","status":"RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2025-12-18","conditions":"Sjogren's Syndrome","enrollment":60},{"nctId":"NCT05104723","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-12","conditions":"Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease","enrollment":20},{"nctId":"NCT01500551","phase":"PHASE2, PHASE3","title":"Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-03-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":302},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT06095128","phase":"PHASE4","title":"A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-06-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT05754710","phase":"","title":"Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-04-12","conditions":"Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis","enrollment":10},{"nctId":"NCT07406035","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Psoriatic Arthritis","enrollment":156},{"nctId":"NCT07055529","phase":"EARLY_PHASE1","title":"Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-06-01","conditions":"Vitiligo, Generalized","enrollment":64},{"nctId":"NCT04496960","phase":"PHASE1, PHASE2","title":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2021-05-18","conditions":"Sjogren's Syndrome","enrollment":23},{"nctId":"NCT04246372","phase":"PHASE2","title":"Tofacitinib for Immune Skin Conditions in Down Syndrome","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-10-21","conditions":"Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema","enrollment":47},{"nctId":"NCT04431895","phase":"EARLY_PHASE1","title":"Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-11","conditions":"Myasthenia Gravis, Generalized","enrollment":19},{"nctId":"NCT06998875","phase":"PHASE4","title":"A Prospective Cohort Study on Primary Cutaneous Amyloidosis","status":"RECRUITING","sponsor":"Army Medical University, China","startDate":"2025-03-01","conditions":"Primary Cutaneous Amyloidosis","enrollment":56},{"nctId":"NCT03000439","phase":"PHASE3","title":"A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-05-10","conditions":"Arthritis Juvenile Idiopathic","enrollment":100},{"nctId":"NCT04415151","phase":"PHASE2","title":"Tofacitinib for Treatment of Moderate COVID-19","status":"TERMINATED","sponsor":"Yale University","startDate":"2020-10-14","conditions":"COVID-19 Pneumonia","enrollment":24},{"nctId":"NCT06887127","phase":"PHASE3","title":"A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2025-03-10","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT04985955","phase":"PHASE1","title":"A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-07-30","conditions":"Healthy","enrollment":12},{"nctId":"NCT03976245","phase":"PHASE4","title":"Advanced Therapeutics in Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-03-01","conditions":"Rheumatoid Arthritis","enrollment":144},{"nctId":"NCT06707246","phase":"NA","title":"A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-12-15","conditions":"Hidradenitis Suppurativa","enrollment":60},{"nctId":"NCT06689982","phase":"EARLY_PHASE1","title":"Tofacitinib in Patients With Amyotrophic Lateral Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-12-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT01932372","phase":"","title":"Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07-26","conditions":"Rheumatoid Arthritis","enrollment":9968},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT05102448","phase":"PHASE4","title":"Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-11-01","conditions":"Takayasu Arteritis","enrollment":76},{"nctId":"NCT03643211","phase":"","title":"Xeljanz Special Investigation for Long-term Use in UC Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-08","conditions":"Ulcerative Colitis","enrollment":2016},{"nctId":"NCT03981900","phase":"","title":"IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-04","conditions":"Arthritis, Rheumatoid","enrollment":314},{"nctId":"NCT05814939","phase":"PHASE2","title":"Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2023-04-26","conditions":"Active Ankylosing Spondylitis","enrollment":180},{"nctId":"NCT06176508","phase":"PHASE2","title":"Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-02-26","conditions":"Psoriatic Arthritis","enrollment":160},{"nctId":"NCT04311567","phase":"PHASE4","title":"Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease","status":"TERMINATED","sponsor":"Vastra Gotaland Region","startDate":"2020-11-07","conditions":"Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), RA","enrollment":3},{"nctId":"NCT00847613","phase":"PHASE3","title":"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Arthritis, Rheumatoid","enrollment":800},{"nctId":"NCT06201715","phase":"NA","title":"Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-05-01","conditions":"Prurigo Nodularis, Itch","enrollment":24},{"nctId":"NCT03980483","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-05-16","conditions":"Arthritis, Rheumatoid","enrollment":1537},{"nctId":"NCT06146972","phase":"PHASE4","title":"Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Yanfeng Hou","startDate":"2021-06-01","conditions":"Rheumatoid Arthritis, Therapy","enrollment":117},{"nctId":"NCT03486457","phase":"PHASE3","title":"Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-08-10","conditions":"Psoriatic Arthritis","enrollment":204},{"nctId":"NCT06114407","phase":"PHASE2","title":"Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-10-30","conditions":"Spondyloarthritis, Axial","enrollment":184},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT06119490","phase":"EARLY_PHASE1","title":"Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis","status":"RECRUITING","sponsor":"Peng Zhang","startDate":"2023-07-05","conditions":"Toxic Epidermal Necrolysis","enrollment":30},{"nctId":"NCT06020144","phase":"PHASE3","title":"A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs","status":"UNKNOWN","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-11-15","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT04928066","phase":"PHASE4","title":"The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-03-01","conditions":"Arthritis, Rheumatoid","enrollment":100},{"nctId":"NCT05133297","phase":"PHASE2","title":"The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-02-16","conditions":"Rheumatoid Arthritis","enrollment":101},{"nctId":"NCT04267380","phase":"","title":"A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-30","conditions":"Arthritis Rheumatoid","enrollment":298},{"nctId":"NCT03281304","phase":"PHASE4","title":"A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-11-16","conditions":"Ulcerative Colitis","enrollment":140},{"nctId":"NCT04552197","phase":"PHASE1","title":"A Study of JNJ-64251330 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT04062695","phase":"PHASE2","title":"Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2020-08-04","conditions":"Psoriatic Arthritis, Spondylitis, Sacroilitis","enrollment":80},{"nctId":"NCT05165771","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2022-07","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT03793439","phase":"PHASE1","title":"Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2019-05-15","conditions":"Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis","enrollment":5},{"nctId":"NCT03159936","phase":"EARLY_PHASE1","title":"Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2017-04-03","conditions":"Discoid Lupus Erythematosus, Systemic Lupus Erythematosus","enrollment":5},{"nctId":"NCT04468425","phase":"PHASE1","title":"Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study","status":"COMPLETED","sponsor":"TWi Biotechnology, Inc.","startDate":"2020-10-14","conditions":"Healthy Subjects","enrollment":14},{"nctId":"NCT01470612","phase":"PHASE3","title":"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10-01","conditions":"Ulcerative Colitis","enrollment":944},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT04944524","phase":"PHASE4","title":"Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-07-01","conditions":"Granulomatosis With Polyangiitis","enrollment":66},{"nctId":"NCT03002649","phase":"PHASE1","title":"Study of Tofacitinib in Refractory Dermatomyositis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"Dermatomyositis","enrollment":10},{"nctId":"NCT01743677","phase":"PHASE1","title":"CP-690,550 Thorough QTc Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-10-26","conditions":"Healthy","enrollment":60},{"nctId":"NCT04412252","phase":"PHASE2","title":"Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2020-07-06","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04299971","phase":"PHASE4","title":"Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-03-01","conditions":"Takayasu Arteritis, Methotrexate, Inhibition","enrollment":130},{"nctId":"NCT04403776","phase":"PHASE1","title":"PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-12-03","conditions":"Healthy","enrollment":26},{"nctId":"NCT01976364","phase":"PHASE3","title":"Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-02-17","conditions":"Arthritis, Psoriatic","enrollment":686},{"nctId":"NCT03274076","phase":"PHASE1, PHASE2","title":"Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-09-25","conditions":"Systemic Sclerosis, Scleroderma","enrollment":15},{"nctId":"NCT02592434","phase":"PHASE3","title":"Efficacy Study Of Tofacitinib In Pediatric JIA Population","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-06-10","conditions":"Juvenile Idiopathic Arthritis","enrollment":225},{"nctId":"NCT03868072","phase":"PHASE1","title":"Study to Evaluate the Bioequivalence of Pfizer Korea Inc. \"XELJANZ 5Mg Tablet\" in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-02-22","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT04111614","phase":"PHASE1","title":"A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-11","conditions":"Healthy","enrollment":12},{"nctId":"NCT02831855","phase":"PHASE4","title":"Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-09-01","conditions":"Rheumatoid Arthritis","enrollment":694},{"nctId":"NCT00960440","phase":"PHASE3","title":"Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10","conditions":"Arthritis, Rheumatoid","enrollment":399},{"nctId":"NCT02084875","phase":"PHASE1","title":"A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT02281552","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-11-18","conditions":"Rheumatoid Arthritis","enrollment":209},{"nctId":"NCT02147587","phase":"PHASE2","title":"A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-06","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT01039688","phase":"PHASE3","title":"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Arthritis, Rheumatoid","enrollment":956},{"nctId":"NCT00658359","phase":"PHASE2","title":"Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Kidney Transplantation","enrollment":178},{"nctId":"NCT02312882","phase":"NA","title":"Tofacitinib for the Treatment of Alopecia Areata and Its Variants","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-12","conditions":"Alopecia Areata, Alopecia Totalis, Alopecia Universalis","enrollment":40},{"nctId":"NCT01470599","phase":"PHASE2","title":"A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Crohn's Disease","enrollment":150},{"nctId":"NCT01882439","phase":"PHASE3","title":"Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-08","conditions":"Psoriatic Arthritis","enrollment":395},{"nctId":"NCT01877668","phase":"PHASE3","title":"Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01-20","conditions":"Psoriatic Arthritis","enrollment":422},{"nctId":"NCT01393626","phase":"PHASE2","title":"A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Crohn's Disease","enrollment":280},{"nctId":"NCT01393899","phase":"PHASE2","title":"The Safety And Efficacy Of Maintenance Therapy With CP-690,550","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Crohn's Disease","enrollment":180},{"nctId":"NCT01513902","phase":"PHASE1","title":"Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-03","conditions":"Juvenile Idiopathic Arthritis","enrollment":26},{"nctId":"NCT01786668","phase":"PHASE2","title":"Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Ankylosing Spondylitis","enrollment":208},{"nctId":"NCT02487433","phase":"PHASE1","title":"A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06","conditions":"Healthy","enrollment":18},{"nctId":"NCT01164579","phase":"PHASE2","title":"Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":109},{"nctId":"NCT00687193","phase":"PHASE2","title":"Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Arthritis, Rheumatoid","enrollment":318},{"nctId":"NCT01736696","phase":"PHASE1","title":"Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Psoriasis, Immunomodulation","enrollment":59},{"nctId":"NCT00147498","phase":"PHASE2","title":"Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-01","conditions":"Rheumatoid Arthritis","enrollment":264},{"nctId":"NCT00603512","phase":"PHASE2","title":"Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-01","conditions":"Arthritis, Rheumatoid","enrollment":140},{"nctId":"NCT00413660","phase":"PHASE2","title":"Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01","conditions":"Arthritis, Rheumatoid","enrollment":509},{"nctId":"NCT00853385","phase":"PHASE3","title":"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Rheumatoid Arthritis","enrollment":717},{"nctId":"NCT00856544","phase":"PHASE3","title":"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Arthritis, Rheumatoid","enrollment":795},{"nctId":"NCT00976599","phase":"PHASE2","title":"A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Rheumatoid Arthritis","enrollment":29},{"nctId":"NCT01740362","phase":"PHASE1","title":"Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT00678210","phase":"PHASE2","title":"Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Psoriasis","enrollment":197},{"nctId":"NCT01059864","phase":"PHASE2","title":"Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-02","conditions":"Rheumatoid Arthritis","enrollment":111},{"nctId":"NCT01599377","phase":"PHASE1","title":"Tofacitinib Bioequivalence Study Comparing Tablets And Capsules","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05","conditions":"Healthy","enrollment":50},{"nctId":"NCT01202240","phase":"PHASE1","title":"Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01204112","phase":"PHASE1","title":"Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01184092","phase":"PHASE1","title":"A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT01184001","phase":"PHASE1","title":"A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01185184","phase":"PHASE1","title":"Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT01143805","phase":"PHASE1","title":"A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Healthy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeljanz"],"phase":"marketed","status":"active","brandName":"Tofacitinib tablet","genericName":"Tofacitinib tablet","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tofacitinib inhibits Janus kinase (JAK) enzymes to suppress inflammatory cytokine signaling and reduce immune-mediated inflammation. Used for Rheumatoid arthritis, Ulcerative colitis, Polyarticular course juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}